SIMVASTATIN RESTORES DOWN-REGULATED GATA-6 EXPRESSION IN PULMONARY HYPERTENSIVE RATS

REFERENCES

• Budhiraja R, Tuder R M, Hassoun P M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159–165
   PubMed Web of Science ®Google Scholar
• Botney M D. Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension. Am J Respir Crit Care Med. 1999; 159: 361–364
   PubMed Web of Science ®Google Scholar
• van Albada M E, Schoemaker R G, Kemna M S, et al. The role of increased pulmonary blood flow in pulmonary arterial hypertension. Eur Respir J 2005; 26: 487–493
   PubMed Web of Science ®Google Scholar
• Stenmark K R, Mecham R P. Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 1997; 59: 89–144
   PubMed Web of Science ®Google Scholar
• Sokabe T, Yamamoto K, Ohura N, et al. Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2004; 287: H2027–H2034
   PubMed Web of Science ®Google Scholar
• Davies P F. Flow-mediated endothelial mechanotransduction. Physiol Rev. 1995; 75: 519–560
   PubMed Web of Science ®Google Scholar
• Orkin S H. GATA-binding transcription factors in hematopoietic cells. Blood 1992; 80: 575–581
   PubMed Web of Science ®Google Scholar
• Molkentin J D. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem. 2000; 275: 38949–38952
   PubMed Web of Science ®Google Scholar
• Ting C N, Olson M C, Barton K P, et al. Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 1996; 384: 474–478
   PubMed Web of Science ®Google Scholar
• Tsai F Y, Keller G, Kuo F C, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994; 371: 221–226
   PubMed Web of Science ®Google Scholar
• De Maria R, Zeuner A, Eramo A, et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999; 401: 489–493
   PubMed Web of Science ®Google Scholar
• Orkin S H, Shivdasani R A, Fujiwara Y, et al. Transcription factor GATA-1 in megakaryocyte development. Stem Cells. 1998; 16(Suppl 2)79–83
   PubMedGoogle Scholar
• Patient R K, McGhee J D. The GATA family (vertebrates and invertebrates). Curr Opin Genet Dev 2002; 12: 416–422
   PubMed Web of Science ®Google Scholar
• Yang H, Lu M M, Zhang L, et al. GATA6 regulates differentiation of distal lung epithelium. Development 2002; 129: 2233–2246
   PubMed Web of Science ®Google Scholar
• Morrisey E E, Ip H S, Lu M M, et al. GATA-6: a zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm. Dev Biol 1996; 177: 309–322
   PubMed Web of Science ®Google Scholar
• Fischer A, Klattig J, Kneitz B, et al. Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts. Mol Cell Biol 2005; 25: 8960–8970
   PubMed Web of Science ®Google Scholar
• Zhao R, Watt A J, Li J, et al. GATA6 is essential for embryonic development of the liver but dispensable for early heart formation. Mol Cell Biol 2005; 25: 2622–2631
   PubMed Web of Science ®Google Scholar
• Suzuki E, Evans T, Lowry J, et al. The human GATA-6 gene: structure, chromosomal location, and regulation of expression by tissue-specific and mitogen-responsive signals. Genomics 1996; 38: 283–290
   PubMed Web of Science ®Google Scholar
• Perlman H, Suzuki E, Simonson M, et al. GATA-6 induces p21(Cip1) expression and G1 cell cycle arrest. J Biol Chem 1998; 273: 13713–13718
   PubMed Web of Science ®Google Scholar
• Mano T, Luo Z, Malendowicz S L, et al. Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery. Circ Res 1999; 84: 647–654
   PubMed Web of Science ®Google Scholar
• Morrisey E E. GATA-6: the proliferation stops here: cell proliferation in glomerular mesangial and vascular smooth muscle cells. Circ Res. 2000; 87: 638–640
   PubMed Web of Science ®Google Scholar
• Sokabe T, Yamamoto K, Ohura N, et al. Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2004; 287: H2027–H2034
   PubMed Web of Science ®Google Scholar
• Lepore J J, Cappola T P, Mericko P A, et al. GATA-6 regulates genes promoting synthetic functions in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2005; 25: 309–314
   PubMed Web of Science ®Google Scholar
• Mishra T K, Routray S. Current perspectives on statins. J Indian Med Assoc 2003; 101: 381–383
   PubMedGoogle Scholar
• Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399–1402
   PubMed Web of Science ®Google Scholar
• Bustos C, Hernandez-Presa M A, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057–2064
   PubMed Web of Science ®Google Scholar
• Indolfi C, Cioppa A, Stabile E, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000; 35: 214–221
   PubMed Web of Science ®Google Scholar
• Laufs U, Marra D, Node K, et al. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999; 274: 21926–21931
   PubMed Web of Science ®Google Scholar
• Laufs U, Fata V L, Liao J K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725–31729
   PubMed Web of Science ®Google Scholar
• Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004–1010
   PubMed Web of Science ®Google Scholar
• Nishimura T, Vaszar L T, Faul J L, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation JT – Circulation 2003; 108: 1640–1645
   PubMed Web of Science ®Google Scholar
• Nishimura T, Faul J L, Berry G J, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002; 166: 1403–1408
   PubMed Web of Science ®Google Scholar
• Girgis R E, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol. 2003; 285: H938–H945
   PubMed Web of Science ®Google Scholar
• Wada H, Abe M, Ono K, et al. Statins activate GATA-6 and induce differentiated vascular smooth muscle cells. Biochem Biophys Res Commun 2008; 374: 731–736
   PubMed Web of Science ®Google Scholar
• Okada K, Tanaka Y, Bernstein M, et al. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 1997; 151: 1019–1025
   PubMed Web of Science ®Google Scholar
• Faul J L, Nishimura T, Berry G J, et al. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2000; 162: 2252–2258
   PubMed Web of Science ®Google Scholar
• Nishimura T, Faul J L, Berry G J, et al. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2001; 163: 498–502
   PubMed Web of Science ®Google Scholar
• Hoshikawa Y, Ono S, Suzuki S, et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 2001; 90: 1299–1306
   PubMed Web of Science ®Google Scholar
• Fishman A P, Fishman M C, Freeman B A, et al. Mechanisms of proliferative and obliterative vascular diseases. Insights from the pulmonary and systemic circulations. NHLBI Workshop summary. Am J Respir Crit Care Med 1998; 158: 670–674
   PubMed Web of Science ®Google Scholar
• Newman J H, Lane K B. Hypertensive pulmonary vascular disease: dawn of the age of prevention?. Am J Respir Crit Care Med 2000; 162: 2020–2021
   PubMed Web of Science ®Google Scholar
• Kao P N, Faul J L. Emerging therapies for pulmonary hypertension: striving for efficacy and safety. J Am Coll Cardiol 2003; 41: 2126–2129
   PubMed Web of Science ®Google Scholar
• Rubin L J. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med. 2002; 166: 1308–1309
   PubMed Web of Science ®Google Scholar
• Newman J H, Fanburg B L, Archer S L, et al. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 2004; 109: 2947–2952
   PubMed Web of Science ®Google Scholar
• Chan A W, Bhatt D L, Chew D P, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691–696
   PubMed Web of Science ®Google Scholar
• Heeschen C, Hamm C W, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446–1452
   PubMed Web of Science ®Google Scholar
• Epstein M, Campese V M. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005; 45: 2–14
   PubMed Web of Science ®Google Scholar
• Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81: 153–208
   PubMed Web of Science ®Google Scholar
• Rikitake Y, Liao J K. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232–1235
   PubMed Web of Science ®Google Scholar
• Stark W W, Jr, Blaskovich M A, Johnson B A, et al. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol. 1998; 275(1)L55–L63, Pt 1
   PubMed Web of Science ®Google Scholar
• Hernandez-Perera O, Perez-Sala D, Soria E, et al. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87: 616–622
   PubMed Web of Science ®Google Scholar
• Xu C B, Stenman E, Edvinsson L. Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol 2002; 64: 497–505
   PubMed Web of Science ®Google Scholar
• Kalinowski L, Dobrucki L W, Brovkovych V, et al. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 2002; 105: 933–938
   PubMed Web of Science ®Google Scholar
• Weissmann N, Winterhalder S, Nollen M, et al. NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. Am J Physiol Lung Cell Mol Physiol. 2001; 280: L638–L645
   PubMed Web of Science ®Google Scholar
• Sun-Wada G H, Kamei Y, Wada Y, et al. Regulatory elements directing gut expression of the GATA6 gene during mouse early development. J Biochem (Tokyo) 2004; 135: 165–169
   PubMed Web of Science ®Google Scholar
• Narita N, Heikinheimo M, Bielinska M, et al. The gene for transcription factor GATA-6 resides on mouse chromosome 18 and is expressed in myocardium and vascular smooth muscle. Genomics 1998; 36: 345–348
   Web of Science ®Google Scholar
• Arora M, Chen L, Paglia M, et al. Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc Natl Acad Sci U S A 2006; 103: 7777–7782
   PubMed Web of Science ®Google Scholar